Center for Quality, Effectiveness, and Outcomes in Cardiovascular Diseases, Houston, TX; Department of Vascular Surgery, Long School of Medicine, San Antonio, TX.
Center for Quality, Effectiveness, and Outcomes in Cardiovascular Diseases, Houston, TX; Division of Vascular Surgery, Medical College of Wisconsin, Milwaukee, WI.
J Vasc Surg. 2024 Aug;80(2):545-553.e3. doi: 10.1016/j.jvs.2024.03.445. Epub 2024 Apr 9.
Failure to achieve timely arteriovenous fistulae (AVFs) utilization due to excessive depth (>6 mm) remains an ongoing concern for dialysis access. This study evaluates the outcomes of radiocephalic (RCF) and brachiocephalic (BCF) fistula elevation required for access utilization.
A retrospective review of all patients undergoing first-time autologous access over 10 years was undertaken. RCF and BCF were analyzed, and cases of initial access failure due to depth alone were selected for study. Primary and staged brachio-basilic AVF were excluded. Outcomes of early thrombosis, line placement, maturation (successful progression to hemodialysis [HD), reintervention, and functional dialysis (continuous HD for 3 consecutive months) were examined.
From January 2012 to December 2022, 1733 patients (67% female; mean age, 61 ± 14 years) underwent autologous AVF placement. Of these, 298 patients (17%) had depth-related AVF access issues (BCF, 71% and RCF, 29%). Nineteen percent of these AVFs underwent a primary balloon-assisted maturation (BAM), and 2% had side branch coil embolization before consideration for elevation. The average time to intervention for depth was 11 ± 4 weeks after primary creation. During elevation, side branch ligation occurred in 38% of cases, and 15% underwent intraoperative BAM, The pre-elevation depth was 8.2 ± 3.1 mm, and the mean post-elevation depth was 4.7 ± 2.9 mm (P = .002). Early thrombosis (<18 days) occurred in 4% of cases. There was no mortality, and the 30-day major adverse cardiac event rate was 2%, with a 30-day morbidity of 5%, which was driven by wound issues. Six percent of the AVFs underwent follow-up BAM within 3 months. Mean maturation of the AVFs was 74% ± 3% vs 72% ± 3% (P = .58) for the elevation vs no-elevation groups at 24 weeks, respectively. However, there was an increase in tunneled central line placement in pre-emptive fistula patients due to the delay in maturation (elevation, 17% vs no-elevation, 8%; P = .008). There was a mean successful access time of 6 ± 3 weeks after elevation (16 ± 4 weeks after access creation). There was a median of 2.4 secondary interventions per year after elevation compared with a median of 2.7 secondary interventions per year without elevation. Mean access functionality was 68% ± 8% vs 75% ± 8% at 3 years for the elevation vs no-elevation groups, respectively (P = .25).
Elevation of deep BCF and RCF occurs late after placement but can be successfully achieved with low morbidity and satisfactory long-term functionality. It results in an increase in tunneled central line placement in pre-emptive fistula patients. Elevation is a valuable adjunct to AVF maturation and enhances an autologous access policy.
由于深度过大(>6 毫米)而导致动静脉瘘(AVF)无法及时使用仍然是透析通路面临的一个持续问题。本研究评估了为进行血管通路而需要抬高桡动脉(RCF)和头臂动脉(BCF)的结果。
对 10 年来首次进行自体动静脉通路的所有患者进行了回顾性分析。分析了 RCF 和 BCF,并选择了由于深度原因导致初始通路失败的病例进行研究。排除了原发性和分期肱-肱浅静脉 AVF。检查了早期血栓形成、置管、成熟(成功进展至血液透析[HD])、再介入和功能透析(连续 HD 治疗 3 个月)的结果。
2012 年 1 月至 2022 年 12 月,1733 例患者(67%为女性;平均年龄 61±14 岁)接受了自体 AVF 置入。其中 298 例(17%)有与深度相关的 AVF 通路问题(BCF 占 71%,RCF 占 29%)。这些 AVF 中有 19%接受了原发性球囊辅助成熟(BAM),2%在考虑抬高前进行了侧支线圈栓塞。初次造瘘后 11±4 周进行深度干预的平均时间。在抬高过程中,38%的病例发生侧支结扎,15%的病例在术中进行 BAM。术前深度为 8.2±3.1 毫米,平均抬高后深度为 4.7±2.9 毫米(P=0.002)。早期血栓形成(<18 天)的发生率为 4%。无死亡病例,30 天主要心脏不良事件发生率为 2%,30 天发病率为 5%,主要由伤口问题引起。6%的 AVF 在 3 个月内接受了随访 BAM。抬高组 AVF 的成熟度分别为 74%±3%和 72%±3%(P=0.58),在 24 周时分别为抬高组和未抬高组。然而,由于成熟延迟,预防性造瘘患者的隧道中央置管增加(抬高组 17%,未抬高组 8%;P=0.008)。抬高后平均成功通路时间为 6±3 周(通路建立后 16±4 周)。与未抬高组相比,抬高组每年需要进行 2.4 次次要干预,而未抬高组每年需要进行 2.7 次次要干预。与未抬高组相比,抬高组 AVF 的功能分别为 68%±8%和 75%±8%,在 3 年时(P=0.25)。
BCF 和 RCF 深度抬高发生在造瘘后较晚,但可通过较低的发病率和令人满意的长期功能成功实现。它导致预防性造瘘患者的隧道中央置管增加。抬高是 AVF 成熟的有效辅助手段,并增强了自体动静脉通路策略。